Kindler’s Honeymoon Over? Analysts Press Pfizer Execs On Series Of Stumbles
Executive Summary
The sheen of Pfizer's new management team - including CEO Jeffrey Kindler - may be beginning to wear off, based on analyst comments during Pfizer's April 20 first-quarter earnings call
You may also be interested in...
Pharma Awaits Market Impact Of Added FDA Bill Safety Proposals, IMS Says
FDA's safety assessments may serve as the wildcard for how the pharmaceutical market will play out in 2008, IMS says, as the agency evaluates safety priorities and implements additional postmarket review strategies authorized by the FDA Amendments Act
Pharma Awaits Market Impact Of Added FDA Bill Safety Proposals, IMS Says
FDA's safety assessments may serve as the wildcard for how the pharmaceutical market will play out in 2008, IMS says, as the agency evaluates safety priorities and implements additional postmarket review strategies authorized by the FDA Amendments Act
Pfizer opening to investor input
Pfizer is taking further steps to increase transparency and allay investors' concerns about executive compensation; the company's board will meet with the largest institutional shareholders this fall to discuss its governance and compensation policies. Investors had grown frustrated with former CEO Hank McKinnell, and Pfizer's performance, which was exacerbated by McKinnell's severance package of nearly $200 million (1"The Pink Sheet" Jan. 1, 2007, In Brief). Despite taking the firm in a new direction with a major restructuring, patience with CEO Jeffrey Kindler may already be waning (2"The Pink Sheet" April 30, 2007, p. 6)...